

Evaluation of *Crocus sativus* L. (saffron) on male erectile dysfunction: A pilot study

Ali Shamsa^a, Hossein Hosseinzadeh^{b,*}, Mahmood Molaei^a,
Mohammad Taghi Shakeri^c, Omid Rajabi^d

^aUrology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

^bPharmacology and Toxicology Department, Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

^cDepartment of Biostatistics, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

^dPharmaceutical Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

In this study, the effect of *Crocus sativus* (saffron) was studied on male erectile dysfunction (ED). Twenty male patients with ED were followed for ten days in which each morning they took a tablet containing 200 mg of saffron. Patients underwent the nocturnal penile tumescence (NPT) test and the international index of erectile function questionnaire (IIEF-15) at the start of the treatment and at the end of the ten days. After the ten days of taking saffron there was a statistically significant improvement in tip rigidity and tip tumescence as well as base rigidity and base tumescence. IIEF-15 total scores were significantly higher in patients after saffron treatment (before treatment 22.15 ± 1.44 ; after treatment 39.20 ± 1.90 , $p < 0.001$). Saffron showed a positive effect on sexual function with increased number and duration of erectile events seen in patients with ED even only after taking it for ten days.

© 2009 Elsevier GmbH. All rights reserved.

Keywords: *Crocus sativus*; Saffron; Erectile dysfunction; Sexual activity; RigiScan; International index of erectile function questionnaire (IIEF-15)

Introduction

Erectile dysfunction (ED) affects more than 150 million males throughout the world (Porst et al. 2003). For the minority of causes, phosphodiesterase 5-inhibitors, like sildenafil, tadalafil and vardenafil work to resolve ED, however due to various reasons such as adverse side-effects, cost and drug interactions many men stop using them and seek further help.

Saffron is the dried red stigma collected from the saffron plant (*Crocus sativus* L., Iridaceae family) which

is widely cultivated in Iran (Ríos et al. 1996). Saffron has different activities such as anticancer (Nair et al. 1995; Abdullaev and Espinosa-Aguirre 2004), anticonvulsant (Hosseinzadeh and Khosravan 2002; Hosseinzadeh and Talebzadeh 2005), antidepressant (Hosseinzadeh et al. 2004; Akhondzadeh et al. 2005), anti-ischemia (Hosseinzadeh and Sadeghnia 2005; Hosseinzadeh et al. 2005), learning and memory improving properties (Abe and Saito 2000; Hosseinzadeh and Ziaei 2006). In traditional medicine, saffron is recommended as aphrodisiac agent (Madan et al. 1966). Recently, an aphrodisiac activity of saffron aqueous extract and its constituent crocin was shown in rat. Crocin, and saffron increased mounting, intromission and erection

*Corresponding author. Fax: +98 5118823251.

E-mail address: hosseinzadehh@mums.ac.ir (H. Hosseinzadeh).

frequency behaviors during the sexual behavior study in rats (Hosseinzadeh et al. 2008). Thus, in this study the effect of saffron tablets was evaluated in patients with ED.

Materials and methods

Study design

This open clinical trial was conducted to evaluate the effect of saffron on 20 male patients with ED. The treatment period was for ten days, during this period patients received a tablet containing 200 mg of saffron each morning, except on the last day (day 10) where patients were scheduled for a Rigiscan, and thus each took double the dose of saffron.

In all ED patients, we advise vasoactive drugs injection in corpus spongiosum in office, before color Doppler sonography of penis as well as cavernosography and cavernosometry, also Rigiscan as needed. When it was clear that there is no underlying cause for ED, for example, diabetes mellitus (idiopathic) then, patients were included in the study.

60 percent of our patients were on long-term prescribed medication, but the other came for treatment for the first time.

Major exclusion criteria were when the cause of ED is clear, e.g. pelvic fracture, diabetes mellitus, etc.

Patients were voluntary consented and told about the drug. The age ranged between 26 to 62 years (43.78 ± 10.61). Before taking the tablets, patients asked to come to the Rigiscan room inside the urology department.

A single and isolated bedroom with a RigiScan, computer, printer and all other relevant equipment was prepared. The nocturnal penile tumescence (NPT) test was conducted during the night, for ten hours duration.

After removal of the RigiScan device and printing the profile, the international index of erectile function with 15 questions (IIEF-15) was applied to each patient. Thereafter on discharge patients were told to take one tablet daily except on day ten, where two tablets were taken and the second NPT test was conducted followed by the IIEF-15 once the rigiscan was removed.

There was no complication related neither to RigiScan test nor saffron usage.

Plant material

Crocus sativus L. stigma was taken from Novin Saffron Co. Mashhad, IR, Iran. It was formulated as tablets which each tablet contained 200 mg dried saffron stigma.

Quantification of crocin and safranal in saffron aqueous extract

Amounts of crocin and safranal in saffron aqueous extract were determined by a modified method as previously described (Hosseinzadeh et al. 2008). The quantities of crocin and safranal in *C. sativus* extract were about 19.7 and 0.25 mg/g, respectively.

Statistical analysis

The results obtained are expressed mean \pm SEM and analyzed using Student's paired *t*-test. A value of $p < 0.05$ was considered statistically significant.

Results

All 20 participants returned after ten days for their second NPT and second IIEF-15. There was a statistically significant difference in tip rigidity and tip tumescence as well as base rigidity and base tumescence. Saffron tablets improved all these parameters ($p < 0.0001$) (Table 1).

Mean scores for the erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction were increased significantly after saffron treatment ($p < 0.0001$) (Table 2).

No major adverse events were reported during the clinical trial.

Discussion

Our research showed that saffron improved Rigiscan parameters (rigidity and tumescence) and sexual function domains: erectile function, sexual satisfaction, orgasm, sexual desire and overall satisfaction.

There is a growing worldwide trend in use of alternative medicine especially herbal medicine. For example Kaphle et al. (2006) investigated over a

Table 1. Effect of saffron tablets usage on number of episode per night and RigiScan parameters before and after treatment.

Parameters	Before treatment	After treatment	<i>p</i> value
Number of episode per night	1.85 ± 0.17	3.70 ± 0.26	$p < 0.0001$
Rigidity (%)			
Tip	33.65 ± 3.57	55.05 ± 3.63	$p < 0.0001$
Base	33.85 ± 3.11	57.25 ± 3.21	$p < 0.0001$
Tumescence (cm)			
Tip	1.11 ± 0.13	2.09 ± 0.14	$p < 0.0001$
Base	1.41 ± 0.14	2.53 ± 0.14	$p < 0.0001$

Table 2. Effect of saffron usage on IIEF-15 scores in nocturnal penile tumescence (NPT) test before and after treatment.

Parameters	Before treatment	After treatment	<i>p</i> value
Total IIEF score	25.15±1.44	39.20±1.90	<i>p</i> <0.0001
Domains			
Erectile function	11.75±0.92	17.15±0.71	<i>p</i> <0.0001
Sexual desire	3.80±0.22	6.10±0.32	<i>p</i> <0.0001
Intercourse satisfaction	3.85±0.30	6.15±0.39	<i>p</i> <0.0001
Orgasmic function	2.82±0.29	4.80±0.33	<i>p</i> <0.0001
Overall satisfaction	3.00±0.22	5.95±0.49	<i>p</i> <0.0001

hundred herbs *in vivo* and *in vitro* in Taiwan to analyze their effect on steroid hormones especially testosterone. Korean red ginseng showed beneficial effects on erectile dysfunction in terms of subjective relief of symptoms and enhanced penile tip rigidity (Hong et al., 2002).

For centuries among the herbal experts, saffron has been known to have aphrodisiac like properties. However, the validity and efficacy of such a claim had remained uninvestigated. In this study we evaluated and confirmed its effect on ED by using two means: the NPT test and IIEF-15.

Cilurzo et al. (1992) recommended the following criteria as normal NPT: 4–5 erectile episodes per night, mean duration longer than 30 minutes, an increase in circumference of more than 3 cm at the base and more than 2 cm at the tip of penis; and maximal rigidity above 70% at both base and tip of the penis. In our study, all these parameters improved after treatment. However, this improvement did not receive to criteria a normal person.

There is a strong relationship between depression and ED (Shiri et al. 2007). Results from a community study in Malaysia showed erectile function were significantly associated with depression, in that there were a higher proportion of men with ED suffering from depression (Low et al. 2006). In another study in Chinese people, was also demonstrated that “low mood” and “worthlessness” to be important in the association between depressive symptomatology and ED (Cheng et al. 2007). As saffron showed antidepressant effect in basic (Hossein-zadeh et al. 2004) and clinical studies (Akhondzadeh et al. 2005) this effect might be involved in treatment of ED in some patients. However, antidepressant medication may cause ED. Most antidepressant drugs have adverse effects on erectile function. Although it has been reported that use of some antidepressant such as bupropion as monotherapy for depression is associated with lower rates of sexual dysfunction than use of an SSRI, selective serotonin reuptake blockers, such as fluoxetine. In some asses-

ing, bupropion use indicates an improvement in sexual arousal on treatment with it (Taylor et al. 2005).

Saffron and its constituents such as safranal and crocin showed antioxidant and radical scavenging activity in *in vitro* experiments (Assimopoulou et al. 2005). Saffron extract and its constituents safranal and crocin showed a protective effect against lower limb ischemia-reperfusion in rat (Hossein-zadeh et al. 2007). In another study, safranal, one of the constituents of saffron stigmas with monoterpene structure, demonstrated overall protective effect against cerebral ischemia-reperfusion injury-induced oxidative stress in a rat model (Hossein-zadeh and Sadeghnia 2005). Saffron stigma and crocin, a carotenoid constituent of saffron also showed protective effect on ischemia-reperfusion injury-induced oxidative stress in rats' kidneys that at least partly due to antioxidant properties of saffron and crocin (Hossein-zadeh et al. 2005). Thus, saffron may have a beneficial effect on treatment of erectile dysfunction via these effects.

There were some limitations in our study as following: small sample size; no control or placebo group. However, the same patients were used as the control and experimental group post-treatment; the optimum dose of saffron is not known and whether there are any side-effects associated with excess use and the patients were selected randomly, without prior knowledge of their blood parameters that are usually measured in any case of ED.

Regarding adverse effects of saffron, recently it was shown that saffron tablets (200 and/or 400 mg per day) may change some hematological and biochemical parameters. However, these alterations were in normal ranges and they were not important clinically (Modagheh et al. 2008).

At the moment, the high price of saffron may be a barrier to utilize this plant for sexual dysfunctions. However, this study may help to find new agents to treat these disorders.

Conclusions

In the present study, it is shown that saffron has a significant effect on men with erectile dysfunction using NPT and IIEF-15 tests. Whether it is possible to replace phosphodiesterase 5-inhibitors with this golden plant requires further research with a bigger sample size.

Acknowledgements

I would like to thank Dr. Hassan Al-Hashimi of Barts and the London University for his assistance in writing this paper and the Vice Chancellor of Research,

Mashhad University of Medical Sciences for financial support.

References

- Abdullaev, F.I., Espinosa-Aguirre, J.J., 2004. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. *Cancer Detect. Prev.* 28, 426–432.
- Abe, K., Saito, H., 2000. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. *Phytother. Res.* 14, 149–152.
- Akhondzadeh, S., Tahmacebi-Pour, N., Noorbala, A.-A., Amini, H., Fallah-Pour, H., Jamshidi, A.-H., Khani, M., 2005. *Crocus sativus* L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytother. Res.* 19, 148–151.
- Assimopoulou, A.N., Sinakos, Z., Papageorgiou, V.P., 2005. Radical scavenging activity of *Crocus sativus* L. extract and its bioactive constituents. *Phytother. Res.* 19, 997–1000.
- Cheng, J.Y., Ng, E.M., Ko, J.S., 2007. Depressive symptomatology and male sexual functions in late life. *J. Affect. Disord.* 104, 225–229.
- Cilurzo, P., Canale, D., Turchi, P., Giorgi, P.M., Menchini Fabris, G.F., 1992. The Rigiscan system in the diagnosis of male sexual impotence. *Arch. Ital. Urol. Nefrol. Androl.* 64 (Suppl 2), 81–85.
- Hong, B., Ji, Y.H., Hong, J.H., Nam, K.Y., Ahn, T.Y., 2002. A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. *J. Urol.* 168, 2070–2073.
- Hosseinzadeh, H., Modagheh, M.H., Saffari, Z., 2007. *Crocus sativus* L. (saffron) extract and its active constituents (crocin and safranal) on ischemia-reperfusion in rat skeletal muscle. *Evid. Based Complement. Alternat. Med.* 25 (Epub ahead of print).
- Hosseinzadeh, H., Karimi, G.H., Niapoor, M., 2004. Antidepressant effects of *Crocus sativus* stigma extracts and its constituents, crocin and safranal, in mice. *Acta Hort.* 650, 435–445.
- Hosseinzadeh, H., Khosravan, V., 2002. Anticonvulsant effects of aqueous and ethanolic extracts of *Crocus sativus* L. stigmas in mice. *Arch. Iran. Med.* 5, 44–47.
- Hosseinzadeh, H., Sadeghnia, H.R., 2005. Safranal, a constituent of *Crocus sativus* (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. *J. Pharm. Pharm. Sci.* 8, 394–399.
- Hosseinzadeh, H., Sadeghnia, H.R., Ziaee, T., Danaee, A., 2005. Protective effect of aqueous saffron extract (*Crocus sativus* L.) and crocin, its active constituent, on renal ischemia-reperfusion-induced oxidative damage in rats. *J. Pharm. Pharm. Sci.* 22, 387–393.
- Hosseinzadeh, H., Talebzadeh, F., 2005. Anticonvulsant evaluation of safranal and crocin from *Crocus sativus* in mice. *Fitoterapia* 76, 722–724.
- Hosseinzadeh, H., Ziaee, T., Sadeghi, A., 2008. The effect of saffron, *Crocus sativus* stigma, extract and its constituents, safranal and crocin on sexual behaviors in normal male rats. *Phytomedicine* 15, 491–495.
- Hosseinzadeh, H., Ziaei, T., 2006. Effects of *Crocus sativus* stigma extract and its constituents, crocin and safranal, on intact memory and scopolamine-induced learning deficits in rats performing the Morris water maze task. *J. Med. Plants* 5, 40–50.
- Kaphle, K., Wu, L.S., Yang, N.Y., Lin, J.H., 2006. Herbal medicine research in Taiwan. *Evid. Based Complement. Alternat. Med.* 3, 149–155.
- Low, W.Y., Khoo, E.M., Tan, H.M., Hew, F.L., Teoh, S.H., 2006. Depression, hormonal status and erectile dysfunction in the aging male: Results from a community study in Malaysia. *J. Men's Health Gender* 3, 263–270.
- Madan, C.L., Kapur, B.M., Gupta, U.S., 1966. Saffron. *Econ. Bot.* 20, 377–385.
- Modagheh, M.H., Shahabian, M., Esmacili, H.A., Rajbai, O., Hosseinzadeh, H., 2008. Safety evaluation of saffron (*Crocus sativus*) tablets in healthy volunteers. *Phytomedicine* 15, 1032–1037.
- Nair, S.C., Kurumboor, S.K., Hasegawa, J.H., 1995. Saffron chemoprevention in biology and medicine: a review. *Cancer Biother.* 10, 257–264.
- Porst, H., Padma-Nathan, H., Giuliano, F., Anglin, G., Varanese, L., Rosen, R., 2003. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. *Urology* 62, 121–126.
- Ríos, J.L., Recio, M.C., Giner, R.M., Mánuez, S., 1996. An update review of saffron and its active constituents. *Phytother. Res.* 10, 189–193.
- Shiri, R., Koskimäki, J., Tammela, T.L., Häkkinen, J., Auvinen, A., Hakama, M., 2007. Bidirectional relationship between depression and erectile dysfunction. *J. Urol.* 177, 669–673.
- Taylor, M.J., Rudkin, L., Hawton, K., 2005. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. *J. Affect. Disord.* 88, 241–254.